In a note out today, Deutsche Bank reiterated a buy rating and $129 price target on biotech firm Biogen Idec BIIB. The price target implies decent upside from current levels. "We continue to see Biogen's BG-12 & Novartis' Gilenya
as having more competitive profiles in terms of oral products for MS," Deutsche Bank said in the note.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorNewsPrice TargetReiterationFDAIntraday UpdateMarketsAnalyst RatingsTrading Ideas
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in